ATE403653T1 - Pyridin-substituierte furanderivate als raf- kinase inhibitoren - Google Patents

Pyridin-substituierte furanderivate als raf- kinase inhibitoren

Info

Publication number
ATE403653T1
ATE403653T1 AT02777001T AT02777001T ATE403653T1 AT E403653 T1 ATE403653 T1 AT E403653T1 AT 02777001 T AT02777001 T AT 02777001T AT 02777001 T AT02777001 T AT 02777001T AT E403653 T1 ATE403653 T1 AT E403653T1
Authority
AT
Austria
Prior art keywords
sub
sup
kinase inhibitors
raf
pyridine
Prior art date
Application number
AT02777001T
Other languages
English (en)
Inventor
Andrew Kenneth Takle
David Matthew Wilson
David Kenneth Dean
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121485A external-priority patent/GB0121485D0/en
Priority claimed from GB0121493A external-priority patent/GB0121493D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE403653T1 publication Critical patent/ATE403653T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02777001T 2001-09-05 2002-09-05 Pyridin-substituierte furanderivate als raf- kinase inhibitoren ATE403653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0121485A GB0121485D0 (en) 2001-09-05 2001-09-05 Compounds
GB0121493A GB0121493D0 (en) 2001-09-05 2001-09-05 Compounds

Publications (1)

Publication Number Publication Date
ATE403653T1 true ATE403653T1 (de) 2008-08-15

Family

ID=26246514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777001T ATE403653T1 (de) 2001-09-05 2002-09-05 Pyridin-substituierte furanderivate als raf- kinase inhibitoren

Country Status (6)

Country Link
US (1) US7375105B2 (de)
EP (1) EP1423383B1 (de)
AT (1) ATE403653T1 (de)
DE (1) DE60228098D1 (de)
ES (1) ES2309207T3 (de)
WO (1) WO2003022838A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1050190A1 (zh) * 1999-11-22 2003-06-13 Smithkline Beecham Plc 咪唑衍生物和它们做为raf激酶抑制剂的用途
JP2003525936A (ja) * 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Rafキナーゼ阻害物質としてのイミダゾール誘導体
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
US7827944B2 (en) * 2006-06-30 2010-11-09 Gm Global Technology Operations, Inc. System for controlling the response time of a hydraulic system
CA2689514C (en) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EP2399921B1 (de) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclische verbindung und deren verwendung
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ, インコーポレイテッド ヘテロアリールおよびその使用
PH12013500274A1 (en) 2010-08-11 2013-03-04 Millennium Pharm Inc Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2814688A1 (en) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2014240950B2 (en) 2013-03-29 2018-11-01 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
WO2017189865A1 (en) 2016-04-27 2017-11-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US5792778A (en) 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
DE69834842T2 (de) 1997-12-22 2007-05-10 Bayer Pharmaceuticals Corp., West Haven Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
AU1596101A (en) * 1999-11-12 2001-06-06 Merck & Co., Inc. Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
NZ518718A (en) * 1999-11-12 2004-03-26 Merck & Co Inc Diaryl piperidyl pyrrole derivatives as antiprotozoal agents, treatment or prophylaxis of coccidiosis
HK1050190A1 (zh) * 1999-11-22 2003-06-13 Smithkline Beecham Plc 咪唑衍生物和它们做为raf激酶抑制剂的用途
JP2002037784A (ja) * 2000-05-17 2002-02-06 Nikken Chem Co Ltd 新規チオフェンアミド化合物

Also Published As

Publication number Publication date
DE60228098D1 (de) 2008-09-18
WO2003022838A8 (en) 2004-03-25
EP1423383B1 (de) 2008-08-06
WO2003022838A1 (en) 2003-03-20
US20040248896A1 (en) 2004-12-09
US7375105B2 (en) 2008-05-20
ES2309207T3 (es) 2008-12-16
EP1423383A1 (de) 2004-06-02

Similar Documents

Publication Publication Date Title
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
ATE454152T1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
ATE300529T1 (de) Imidazolderivate als raf-kinase-inhibitoren
ATE362929T1 (de) Pyridinderivate als inhibitoren der raf-kinase
ATE512957T1 (de) Hemmer der akt aktivität
DE602004023838D1 (de) Hemmer der akt aktivität
EP1737843A4 (de) Hemmer der akt aktivität
ATE381557T1 (de) Rho-kinase inhibitoren
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
TW200611907A (en) Fused heterocyclic compound
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
AU2001235844A1 (en) Imidazol-2-carboxamide derivatives as raf kinase inhibitors
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
ATE266022T1 (de) Imidazol derivate als raf kinase inhibitoren
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
EA200400475A1 (ru) Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
UA98928C2 (ru) 1,4-дигидропиридинконденсированные гетероциклы, способ их получения, применения и композиция, которая содержит их
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
DK1904502T3 (da) Antiarytmiske precursorforbindelser, fremgangsmåder til syntese og fremgangsmåder til anvendelse
EA200700098A1 (ru) Производные 4-арилморфолин-3-она, их получение и их применение в терапии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties